

## **APPOINTMENT OF NEW MEMBERS OF THE SCIENTIFIC COUNCIL**

### **INTRODUCTION**

1. There was a discussion at the last Governing Council (GC) session on how best to achieve a balance of expertise across the Scientific Council (SC) to ensure that the selected new members cover the areas of expertise not well-represented among the remaining SC members.
2. The GC concluded that the Secretariat should provide the outgoing SC members with information on the required areas of expertise as early as possible to allow discussion with their respective GC Representatives. The Secretariat pointed out that having two nominations from each Participating State would permit greater flexibility in achieving the right balance of expertise across the SC as well as allowing consideration of gender balance.
3. The Secretariat assessed the specialities of the SC members leaving after the 59<sup>th</sup> session in 2017 and also the expertise of those remaining and identified the following areas where expertise among incoming members would bring benefit: cancer biology, molecular pathology, prevention and implementation research, cancer biostatistics and cancer metabolism. The Secretariat concluded that sufficient expertise was available in epidemiology, clinical oncology and translational research.
4. In line with the GC request, this information was communicated in October 2016 to the five outgoing SC members to allow time to consider the areas required and to indicate which expertise might be best covered from their country. Selecting two areas for each country would permit the full spectrum of areas to be covered across the five countries concerned. By the time of the 53<sup>rd</sup> session of the SC, no feedback had been received from the outgoing SC members.
5. The Director discussed the required scope of expertise on the SC with the Chairs and Vice-Chairs of both the SC and GC in March 2017. It was agreed that in seeking expertise in cancer biostatistics, consideration should also be given to epidemiologists with a strong methodological background.
6. As per usual practice, the Director sent out the formal request for SC nominations to the five GC Representatives in a letter dated 3 March 2017. The Secretariat suggested areas of expertise to each GC representative, thus aiming to cover the areas required from among those nominations across the five PS concerned. The letter also highlighted that having two nominations would maximize the opportunity for the GC, in making their selections, to achieve a required spread of expertise and to achieve gender balance. However, the Secretariat recognizes that PS may have additional criteria to consider in providing nominations.

7. The areas of expertise requested from each PS were as follows: Austria (Cancer biology or Biostatistics); Brazil (Cancer immunology or Cancer biology); Canada (Biostatistics or Cancer epidemiology); France (Molecular epidemiology or Cancer prevention/implementation research) and Qatar (Cancer health services research/policy or Biostatistics).

8. The areas of expertise of those members remaining on the SC is provided below for consideration by the GC in making its selection of new SC members from among the nominations.

<b>Name</b>	<b>Country</b>	<b>Term of office</b>	<b>Gender</b>	<b>Field of expertise</b>
Professor Stephen J. Chanock	USA	2015 – 2018	M	Genetics; cancer epidemiology
Professor Ellen Kampman	The Netherlands	2015 – 2018	F	Human nutrition; multifactorial causes of cancer, including diet and genetic susceptibility
Dr Ole Raaschou-Nielsen	Denmark	2015 – 2018	M	Epidemiology; cancer, environment; exposure assessment; air pollution and health, especially cancer using a molecular epidemiological approach
Professor Martin Rösli	Switzerland	2015 – 2018	M	Environmental epidemiology, including exposure assessment, etiological research and health risk assessments
Professor Elisabete Weiderpass-Vainio	Finland	2015 – 2018	F	Cancer epidemiology
Dr Boris Ya. Alekseev	Russian Federation	2016 – 2019	M	Clinical oncology; cancer biomarkers; urology
Professor Jonas Bergh	Sweden	2016 – 2019	M	Clinical oncology; cancer biomarkers; breast cancer
Professor Jenny Chang-Claude	Germany	2016 – 2019	F	Genetic epidemiology; breast, ovarian and colorectal cancers
Dr Jerome Coffey	Ireland	2016 – 2019	M	The management of breast and urological cancers, especially testicular germ cell tumours and prostate
Dr Eugenia Dogliotti	Italy	2016 – 2019	F	Mechanisms of DNA repair and mutagenesis; molecular cancer epidemiology
Professor Karima El Rhazi	Morocco	2016 – 2019	F	Cancer epidemiology and public health; cancer control; tobacco and respiratory epidemiology; nutritional epidemiology; quality of life
Professor Kadir Mutlu Hayran	Turkey	2016 – 2019	M	Cancer epidemiology; cancer prevention; cancer clinical trials

Name	Country	Term of office	Gender	Field of expertise
Professor Lalit Kumar	India	2016 – 2019	M	Clinical oncology; bone marrow/stem cell transplantation; multiple myeloma; gynecological malignancies
Dr Dukhyoung Lee	RoK	2016 – 2019	M	Cancer prevention and control; cancer surveillance
Professor Giske Ursin	Norway	2016 – 2019	F	Cancer registration; cancer epidemiology; nutritional epidemiology; gene-environment interactions
Professor Adèle Green	Australia	2017 – 2020	F	Cancer etiology, prevention and implementation research, health services and policy
Professor Atsushi Ochiai	Japan	2017 – 2020	M	Mechanisms of cancer progression, tumour microenvironment, cancer therapeutics
Dr Roberto Salgado	Belgium	2017 – 2020	M	Molecular pathology, solid tumours, in particular breast cancer, circulating tumour biomarkers, next generation sequencing technologies, validation of biomarkers, innovative clinical trials incorporating genomics, quality assurance of genomic technologies
Dr Pilar Sánchez Gómez	Spain	2017 – 2020	F	Brain tumours, preclinical tests, cancer therapeutics, molecular pathology, tumour microenvironment
Professor Simon Tavaré	UK	2017 – 2020	M	Cancer genomics, evolutionary approaches to cancer, statistical bioinformatics for arrays and sequencing, computational biology, population genetics
			TOTAL F = 8 M = 12	

## APPOINTMENT

9. In accordance with Article VI of the Statute and Resolution GC/55/R21, the term of office of five members of the Scientific Council, namely Drs Al-Hareth M. Al-Khater (Qatar), Françoise Clavel-Chapelon (France), Lukas A. Huber (Austria), Luis Felipe Ribeiro Pinto (Brazil) and John J. Spinelli (Canada) will be completed with the 2017 meeting of the Governing Council.

10. For the information of the Council, this leaves the following 20 members (eight women and 12 men) still serving on the Scientific Council: Drs Stephen J. Chanock (USA), Ellen Kampman (The Netherlands), Ole Raaschou-Nielsen (Denmark), Martin Rösli (Switzerland) and Elisabete Weiderpass-Vainio (Finland) until 2018; Drs Boris Alekseev (Russian Federation), Jonas Bergh (Sweden), Jenny Chang-Claude (Germany), Jerome Coffey (Ireland), Eugenia Dogliotti (Italy), Karima El Rhazi (Morocco), Kadir Mutlu Hayran (Turkey), Lalit Kumar (India), Dukhyoung Lee (Republic of Korea) and Giske Ursin (Norway) until 2019; and Drs Adèle Green (Australia), Atsushi Ochiai (Japan), Roberto Salgado (Belgium), Pilar Sánchez Gómez (Spain) and Simon Tavaré (UK) until 2020.

11. In accordance with Article VI.2 of the Agency's Statute, the Governing Council is requested to select new members to be appointed to the Scientific Council from the attached list of experts, one each from Austria, Brazil, Canada, France and Qatar.

*Curricula vitae* are attached\*.

---

\*The *curricula vitae* will be distributed to Governing Council members only.

<p><b>AUSTRIA</b></p> <p>Dr Maria Sibilja Institute of Cancer Research Medical University of Vienna Comprehensive Cancer Center Vienna</p> <p><i>Field:</i> Molecular medicine; tumour immunology; inflammation.</p>	<p><b>BRAZIL</b></p> <p>Dr João P.B. Viola Head, Division of Experimental and Translational Research National Cancer Institute (INCA) Rio de Janeiro</p> <p><i>Field:</i> Tumour immunology; cancer cell transformation.</p>
<p><b>CANADA</b></p> <p>Dr Paul Demers Director, Occupational Cancer Research Center Steering Committee University of Toronto's Dalla Lana School of Public Health Toronto, Ontario</p> <p><i>Field:</i> Occupational and environmental cancers.</p> <p>Dr Christine Friedenreich Head, Division of Preventive Oncology University of Calgary's Department of Oncology Calgary, Alberta</p> <p><i>Field:</i> Cancer etiology, prevention and survival; physical activity.</p>	<p><b>FRANCE</b></p> <p>Dr Jacqueline Clavel Director of Research INSERM Paris</p> <p><i>Field:</i> Environmental epidemiology; childhood cancer; cancer registries.</p>
<p><b>QATAR</b></p> <p>Dr Salha M. Bujassoum Al Bader Program Director for Fellowship Hematology &amp; Oncology Hamad Medical Corporation Doha</p> <p><i>Field:</i> Oncology; breast cancer; cancer screening.</p>	